Advertisement
UK markets close in 8 hours 10 minutes

  • FTSE 100

    7,858.87
    -106.66 (-1.34%)
     

  • FTSE 250

    19,480.82
    -218.07 (-1.11%)
     

  • AIM

    746.35
    -3.93 (-0.52%)
     

  • GBP/EUR

    1.1715
    +0.0004 (+0.04%)
     

  • GBP/USD

    1.2439
    -0.0008 (-0.06%)
     

  • Bitcoin GBP

    50,865.58
    -2,450.08 (-4.60%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CRUDE OIL

    85.74
    +0.33 (+0.39%)
     

  • GOLD FUTURES

    2,389.20
    +6.20 (+0.26%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,234.94
    -365.52 (-2.20%)
     

  • DAX

    17,767.13
    -259.45 (-1.44%)
     

  • CAC 40

    7,917.68
    -127.43 (-1.58%)
     

Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Verona Pharma plc
·2-min read
Verona Pharma plc
Verona Pharma plc

LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 5684286:

  • +1-888-317-6003 for callers in the United States

  • +1-412-317-6061 for international callers

ADVERTISEMENT

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.

For further information please contact:

Verona Pharma plc

US Tel: +1-833-417-0262

UK Tel: +44 (0)203 283 4200

Victoria Stewart, Director of Investor Relations and Communications

info@veronapharma.com

 

 

Argot Partners
(US Investor Enquiries)

Tel: +1-212-600-1902
verona@argotpartners.com

Kimberly Minarovich / Michael Barron

 

 

 

Optimum Strategic Communications
(International Media and European Investor Enquiries)

Tel: +44 (0)203 882 9621
verona@optimumcomms.com

Mary Clark / Rebecca Noonan / Zoe Bolt

 

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.